Efficacy of fluticasone propionate/formoterol fumarate in the treatment of asthma: a pooled analysis.

  title={Efficacy of fluticasone propionate/formoterol fumarate in the treatment of asthma: a pooled analysis.},
  author={A. Papi and D. Price and J. Sastre and K. Kaiser and M. Lomax and T. McIver and S. Dissanayake},
  journal={Respiratory medicine},
  volume={109 2},
BACKGROUND Fluticasone propionate and formoterol fumarate have been combined in a single inhaler (fluticasone/formoterol; flutiform(®)) for the maintenance treatment of asthma. This pooled analysis assessed the efficacy of fluticasone/formoterol versus fluticasone in patients who previously received inhaled corticosteroids. METHODS Data were pooled from five randomised studies in patients with asthma (aged ≥12 years) treated for 8 or 12 weeks with fluticasone/formoterol (100/10, 250/10 or 500… Expand
Short-Term Growth During Treatment with Inhaled Fluticasone Propionate/Formoterol, Fluticasone and Beclomethasone Treatment.
FP/FORM p MDI with AeroChamber and FP pMDI with Volumatic spacer did not affect lower leg growth, measured by knemometry, in asthmatic children, and extra-fine BDP from a breath-actuated inhaler resulted in short-term growth suppression. Expand
The comparison of fluticasone propionate/formoterol with fluticasone propionate/salmeterol for paediatric asthma: a meta-analysis of randomized controlled trials
Overall for paediatric asthma, FP/FORM and FP/SAL demonstrate a comparable influence on FEVj, asthma symptom scores, sleep disturbance scores, and adverse events. Expand
A 12-week open-label, randomized, controlled trial and 24-week extension to assess the efficacy and safety of fluticasone propionate/formoterol in children with asthma
FP/FORM improved lung function and measures of asthma control with comparable efficacy to FP/SAL, and demonstrated a favourable safety and tolerability profile in children aged 4–12 years. Expand
Formoterol and fluticasone propionate combination improves histone deacetylation and anti-inflammatory activities in bronchial epithelial cells exposed to cigarette smoke.
There are compelling evidences that FP combined with FO may contribute to revert some processes related to steroid resistance induced by oxidative stress due to cigarette smoke exposure increasing the anti-inflammatory effects of FP. Expand
Real‐life effectiveness of inhaler device switch from dry powder inhalers to pressurized metred‐dose inhalers in patients with asthma treated with ICS/LABA
This study aimed to assess the persistence and effectiveness of switching from DPI to pMDI for inhaled corticosteroid and long‐acting β2‐agonist combination therapy (ICS/LABA). Expand
Avoiding misdiagnosis in patients with dyspnea and wheezing: a case report illustrating the clinical implications of fixation error
A challenging case characterized by the contemporaneous presence of a common disease, asthma, together with a rare respiratory disease, idiopathic tracheal stenosis is reported, confirming the favorable efficacy and safety profile which are reflected in the recommendations of the international guidelines. Expand
Combinación a dosis fija de fluticasona propionato/formoterol fumarato para el tratamiento del asma: una revisión de la farmacología, eficacia y tolerabilidad
Fluticasona propionato/formoterol constituye una combinacion a dosis fija de glucocorticoide inhalado/agonista β2-adrenergico de accion larga eficaz, rapida, bien tolerada and with un coste de adquisicion razonable. Expand


Superiority of fluticasone propionate/formoterol fumarate versus fluticasone propionate alone in patients with moderate-to-severe asthma: a randomised controlled trial
Results from this study demonstrate that fluticasone/formoterol 250/10 µg b.i.d. provides superior efficacy compared to flutic asone alone for the management of moderate-to-severe asthma, with a safety profile similar to that of fluticAsone monotherapy. Expand
Fluticasone/Formoterol combination therapy compared with monotherapy in adolescent and adult patients with mild to moderate asthma.
Fluticasone/formoterol combination therapy had a good tolerability profile and showed statistically superior efficacy for the two co-primary endpoints compared to fluticas one or formoterol, in adolescents and adults with mild to moderate asthma. Expand
Onset of Bronchodilation with Fluticasone/Formoterol Combination Versus Fluticasone/Salmeterol in an Open-Label, Randomized Study
Fluticasone/formoterol provided a faster onset of bronchodilation than fluticas one/salmeterol, which was maintained over 12 weeks of treatment, and may facilitate treatment adherence among patients with asthma. Expand
Efficacy and safety of fluticasone and formoterol in a single pressurized metered dose inhaler.
It is demonstrated that the fluticasone/formoterol combination is at least as effective as its components administered concurrently from separate inhalers as well as dose-dependent for several clinically important parameters. Expand
Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma.
Fluticasone/formoterol combination therapy was superior to the individual components and placebo for all three co-primary endpoints and demonstrated numerically greater improvements for multiple secondary efficacy analyses. Expand
Safety and efficacy of fluticasone/formoterol combination therapy in adolescent and adult patients with mild-to-moderate asthma: a randomised controlled trial
Overall, the results from multiple secondary endpoints assessing lung function, asthma symptoms, and rescue medication use supported the superior efficacy of the combination product compared with fluticasone, formoterol, and placebo. Expand
Fluticasone/Formoterol Combination Therapy versus Budesonide/Formoterol for the Treatment of Asthma: A Randomized, Controlled, Non-Inferiority Trial of Efficacy and Safety
This study demonstrated comparable efficacy of fluticasone/formoterol to budesonide/ formoterol in terms of the primary endpoint, change in pre-dose FEV1 from baseline to Week 12, and comparable results were obtained for both treatment groups for all other secondary endpoints. Expand
Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study
Fluticasone/formoterol was well tolerated and had a good safety profile that was similar to fluticas one/salmeterol, and has a more rapid onset of action, reflecting the faster bronchodilatory effects of formoterol compared with those of salmeterol. Expand
Long-Term Fluticasone Propionate/Formoterol Fumarate Combination Therapy Is Associated with a Low Incidence of Severe Asthma Exacerbations
The incidence of exacerbations in two fixed-dose fluticasone/formoterol studies was low and less than in the majority of comparable published studies involving other ICS/LABA combinations. Expand
Long-term safety and efficacy of fluticasone/formoterol combination therapy in asthma.
Fluticasone/formoterol had a good safety and efficacy profile over the 6- and 12-month study periods and the efficacy analyses showed statistically significant improvements at every time point throughout the study period at both doses. Expand